Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | PSEN1 | P49768 | 4/20 | 0.44 |
| ▸ | PSEN2 | P49810 | 4/20 | 0.44 |
| ▸ | APH1B | Q8WW43 | 4/20 | 0.44 |
| ▸ | NCSTN | Q92542 | 4/20 | 0.44 |
| ▸ | APH1A | Q96BI3 | 4/20 | 0.44 |
| ▸ | PSENEN | Q9NZ42 | 4/20 | 0.44 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 5/20 | 0.41 |
| ▸ | SOS1 | Q07889 | 2/20 | 0.41 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.41 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.41 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.41 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA4 | P22748 | 1/20 | 0.38 |
| ▸ | CA6 | P23280 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14978748 | 0.84 | PSEN1 (0.41) | TDP1PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL15794097 | 0.82 | IDO1 (0.40) | KMT2APSEN1PSEN2APH1BNCSTN | |
| SCHEMBL1651775 | 0.82 | PTGS2 (0.47) | KMT2APSEN1PSEN2APH1BNCSTN | |
| SCHEMBL20149227 | 0.82 | CA1 (0.61) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL16022234 | 0.82 | PSEN1 (0.41) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL1370049 | 0.82 | PSEN1 (0.41) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL10157192 | 0.80 | HRH4 (0.47) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL22181448 | 0.80 | LMNA (0.52) | KMT2APTGDR2GABRA2 | |
| SCHEMBL17069242 | 0.78 | CA1 (0.37) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL16473931 | 0.77 | PTGDR2 (0.41) | KMT2APSEN1PSEN2APH1BNCSTN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11858879-B2 | PARG inhibitors and method of use thereof | CITY OF HOPE (US) | 2024-01-02 | — | — | US | disclosed |
| US-11858879-B2 | PARG inhibitors and method of use thereof | CITY OF HOPE (US) | 2024-01-02 | — | — | US | disclosed |
| US-20220002231-A1 | PARG INHIBITORS AND METHOD OF USE THEREOF | CITY OF HOPE | 2022-01-06 | — | — | US | disclosed |
| US-10654802-B2 | Indoline derivatives and method for using and producing the same | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNVERSIT (US) | 2020-05-19 | — | — | US | disclosed |
| US-20190135746-A1 | INDOLINE DERIVATIVES AND METHOD FOR USING AND PRODUCING THE SAME | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNVERSITY OF ARIZONA | 2019-05-09 | — | — | US | disclosed |
| US-20140256756-A1 | PIPERIDINYL-SUBSTITUTED LACTAMS AS GPR119 MODULATORS | ARRAY BIOPHARMA, INC. | 2014-09-11 | — | — | US | disclosed |
| US-20140256756-A1 | PIPERIDINYL-SUBSTITUTED LACTAMS AS GPR119 MODULATORS | ARRAY BIOPHARMA, INC. | 2014-09-11 | — | — | US | disclosed |
| US-20140256756-A1 | PIPERIDINYL-SUBSTITUTED LACTAMS AS GPR119 MODULATORS | ARRAY BIOPHARMA, INC. | 2014-09-11 | — | — | US | disclosed |
| US-8354403-B2 | Pyrrolidine derived beta 3 adrenergic receptor agonists | MERCK SHARP & DOHME CORP. (US) | 2013-01-15 | — | — | US | disclosed |
| US-8354403-B2 | Pyrrolidine derived beta 3 adrenergic receptor agonists | MERCK SHARP & DOHME CORP. (US) | 2013-01-15 | — | — | US | disclosed |
| US-20120157432-A1 | NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS | MERCK SHARP & DOHME, CORP. (US) | 2012-06-21 | — | — | US | disclosed |
| US-20120157432-A1 | NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS | MERCK SHARP & DOHME, CORP. (US) | 2012-06-21 | — | — | US | disclosed |
| US-7550458-B2 | Tricycloundecane compounds useful as modulators of nuclear hormone receptor function | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-06-23 | — | — | US | disclosed |
| US-7550458-B2 | Tricycloundecane compounds useful as modulators of nuclear hormone receptor function | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-06-23 | — | — | US | disclosed |
| US-20070088029-A1 | Tricycloundecane compounds useful as modulators of nuclear hormone receptor function | BRISTOL-MYERS SQUIBB COMPANY | 2007-04-19 | — | — | US | disclosed |
| US-20070088029-A1 | Tricycloundecane compounds useful as modulators of nuclear hormone receptor function | BRISTOL-MYERS SQUIBB COMPANY | 2007-04-19 | — | — | US | disclosed |
| US-20070078146-A1 | Antiinflamamtory agents; antiarthritic agents; inflammatory bowel disorders; multiple sclerosis; asthma | PHARMACIA CORPORATION | 2007-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140256756-A1 | PIPERIDINYL-SUBSTITUTED LACTAMS AS GPR119 MODULATORS | GPR119, GPR139, GLP1R | KMT2A 2550/4885TDP1 4840/4885PSEN1 1352/4885 |
| US-20220002231-A1 | PARG INHIBITORS AND METHOD OF USE THEREOF | PARG, PARP12, PARP15 | KMT2A 1009/4885TDP1 284/4885PSEN1 3715/4885 |
| US-10654802-B2 | Indoline derivatives and method for using and producing the same | IDO1, IDO2, MMP1 | KMT2A 2649/4885TDP1 1931/4885PSEN1 873/4885 |
| US-20190135746-A1 | INDOLINE DERIVATIVES AND METHOD FOR USING AND PRODUCING THE SAME | IDO1, INMT, MMP1 | KMT2A 3007/4885TDP1 2216/4885PSEN1 1169/4885 |
| US-20070078146-A1 | Antiinflamamtory agents; antiarthritic agents; inflammatory bowel disorders; multiple sclerosis; asthma | MAPK1, MAPK3, MAPK4 | KMT2A 1449/4885TDP1 1869/4885PSEN1 4835/4885 |
| US-20120157432-A1 | NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS | ADRB3, ADRB1, ADRB2 | KMT2A 4265/4885TDP1 2895/4885PSEN1 2105/4885 |
| US-20070088029-A1 | Tricycloundecane compounds useful as modulators of nuclear hormone receptor function | VDR, ESRRB, NR5A1 | KMT2A 3983/4885TDP1 2080/4885PSEN1 4113/4885 |
| US-11858879-B2 | PARG inhibitors and method of use thereof | PARG, PARP12, PARP15 | KMT2A 1009/4885TDP1 284/4885PSEN1 3715/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.